Former DYAX shareholders get $4/sh CVR milestone payment from FDA approval of SHPG’s Takhzyro (f/k/a DX-2930) for HAE preventive use: https://finance.yahoo.com/news/shire-announces-fda-approval-takhzyro-060000988.html